MX336321B - 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer. - Google Patents
99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer.Info
- Publication number
- MX336321B MX336321B MX2010003829A MX2010003829A MX336321B MX 336321 B MX336321 B MX 336321B MX 2010003829 A MX2010003829 A MX 2010003829A MX 2010003829 A MX2010003829 A MX 2010003829A MX 336321 B MX336321 B MX 336321B
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- radiopharmaceutical
- bombesin
- tat
- mtc
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention refers to a novel radiopharmaceutical of Technetium-99m-N2S2-TAT (49- 57)-Lys3-Bombesin as an agent for the diagnosis of breast cancer by gammagraphic images, which is able to detect in vivo the overexpression of GRP receptors in MCF7 and MDA-MB231 cells of human breast cancer. Likewise, due to the internalization of the Tc-99m radionuclide into the PC-3 cells of prostate cancer and MCF7 and MDA-MB231 of breast cancer, the radiopharmaceutical may be used as a therapeutic agent. The purpose of the present invention is to provide a novel specific radiopharmaceutical (molecular target radiopharmaceutical) for a diagnosis and possible therapy of breast cancer, which is totally different from those currently available on the market.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010003829A MX336321B (en) | 2010-04-08 | 2010-04-08 | 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010003829A MX336321B (en) | 2010-04-08 | 2010-04-08 | 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer. |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2010003829A MX2010003829A (en) | 2011-10-31 |
MX336321B true MX336321B (en) | 2016-01-12 |
Family
ID=45789268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010003829A MX336321B (en) | 2010-04-08 | 2010-04-08 | 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer. |
Country Status (1)
Country | Link |
---|---|
MX (1) | MX336321B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104324394A (en) * | 2014-11-05 | 2015-02-04 | 成都药航科技有限公司 | Molecular probe developer, as well as preparation method and application thereof |
RU2720801C1 (en) * | 2019-02-11 | 2020-05-13 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | RADIONUCLIDE DIAGNOSTIC TECHNIQUE FOR BREAST CANCER WITH Her2/neu HYPEREXPRESSION |
-
2010
- 2010-04-08 MX MX2010003829A patent/MX336321B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2010003829A (en) | 2011-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021003858A (en) | Conjugates for treating diseases caused by psma expressing cells. | |
EA201892668A1 (en) | Tc-EDDA / HYNIC-iPSMA AS A RADIO-PHARMACEUTICAL PRODUCT FOR DETECTION OF SUPEREXPRESSION OF A PROSTATSPECIFIC MEMBRANE ANTIGEN | |
PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
EA201290901A1 (en) | PHYTOCANNABINOIDS FOR THE TREATMENT OF MALIGNANT TUMOR | |
MX2021008976A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer. | |
MX353482B (en) | METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR. | |
PH12015500252A1 (en) | Niclosamide for the treatment of solid tumors | |
EA201290712A1 (en) | ALPHA-RADIATING COMPLEXES | |
MX358517B (en) | Methods for determining drug efficacy using cereblon-associated proteins. | |
MX2013002084A (en) | Biomarkers and methods of treatment. | |
WO2012006421A3 (en) | Diagnosis and treatment of breast cancer | |
WO2012068383A3 (en) | ncRNA AND USES THEREOF | |
EA032867B9 (en) | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates | |
SG10201810357WA (en) | Ly75 as cancer therapeutic and diagnostic target | |
NZ606466A (en) | Peptide radiotracer compositions | |
AR090352A1 (en) | ANTIBODIES AGAINST BRADICININE B1 RECEIVER LIGANDS | |
WO2012007783A8 (en) | Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject | |
WO2009103741A3 (en) | Use of fsh receptor ligands for diagnosis and therapy of cancer | |
IL212800A0 (en) | N-cadherin: target for cancer diagnosis and therapy | |
GB201103696D0 (en) | Technetium labelled peptides | |
MX336321B (en) | 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer. | |
GB201121914D0 (en) | Method for patient selection | |
WO2010127054A3 (en) | Imaging tumor perfusion, and oxidative metabolism using dynamic ace pet in patients with head and neck cancer during radiotherapy | |
MX340487B (en) | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system. | |
WO2013188823A3 (en) | Cancer prognostic assays |